Silverberg Bernstein Capital Management LLC Takes $252,000 Position in Pfizer Inc. (NYSE:PFE)

Silverberg Bernstein Capital Management LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 8,700 shares of the biopharmaceutical company’s stock, valued at approximately $252,000.

A number of other hedge funds also recently made changes to their positions in PFE. Crossmark Global Holdings Inc. grew its stake in shares of Pfizer by 1.4% during the 4th quarter. Crossmark Global Holdings Inc. now owns 78,863 shares of the biopharmaceutical company’s stock valued at $2,271,000 after acquiring an additional 1,107 shares during the period. Schroder Investment Management Group boosted its stake in Pfizer by 14.1% in the 4th quarter. Schroder Investment Management Group now owns 5,650,086 shares of the biopharmaceutical company’s stock worth $162,666,000 after purchasing an additional 698,526 shares during the period. Wealth Quarterback LLC boosted its stake in Pfizer by 15.2% in the 4th quarter. Wealth Quarterback LLC now owns 13,676 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 1,809 shares during the period. Waterloo Capital L.P. bought a new position in Pfizer in the 4th quarter worth approximately $1,334,000. Finally, Vermillion & White Wealth Management Group LLC bought a new position in Pfizer in the 4th quarter worth approximately $233,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PFE has been the subject of several recent analyst reports. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. UBS Group upped their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Barclays upped their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Nine research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Trading Up 0.8 %

Shares of NYSE:PFE traded up $0.24 during trading hours on Friday, hitting $28.58. 28,786,884 shares of the company’s stock traded hands, compared to its average volume of 37,384,395. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $33.92. The business has a fifty day moving average price of $29.17 and a 200-day moving average price of $28.31. The firm has a market capitalization of $161.95 billion, a P/E ratio of -476.33, a price-to-earnings-growth ratio of 1.25 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the previous year, the business earned $0.67 earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.